David Baker
Director/Board Member at GRI BIO, INC.
Net worth: 13 $ as of 31/05/2024
Profile
David C.
Baker was the founder of Vallon Pharmaceuticals, Inc. (founded in 2018) and held the title of Director.
He is currently the Chairman at Philadelphia Education Fund, Director at Benchworks, Inc., and Director at GRI Bio, Inc. Mr. Baker's former positions include President & Chief Executive Officer at Alcobra Ltd.
(2014-2017), Non-Executive Chairman at Devonian Health Group, Inc. (2023-2024), and Vice President-Commercial Strategy & New Business at Shire Pharmaceuticals, Inc. (2004-2013).
He completed his undergraduate degree at Duke University and holds an MBA from The Fuqua School of Business.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GRI BIO, INC.
0.00% | 22/04/2024 | 42 ( 0.00% ) | 13 $ | 31/05/2024 |
| 01/12/2023 | 0 ( -.--% ) | - $ | 31/05/2024 |
David Baker active positions
| Companies | Position | Start |
|---|---|---|
| GRI BIO, INC. | Director/Board Member | - |
| Philadelphia Education Fund | Chairman | - |
Benchworks, Inc.
 Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Director/Board Member | - |
Former positions of David Baker
| Companies | Position | End |
|---|---|---|
| DEVONIAN HEALTH GROUP INC. | Chairman | 03/06/2024 |
| GRI BIOPAR | Chief Executive Officer | 21/04/2023 |
Alcobra Ltd.
 Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Chief Executive Officer | 01/11/2017 |
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Corporate Officer/Principal | 01/12/2013 |
Training of David Baker
| Duke University | Undergraduate Degree |
| The Fuqua School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| GRI BIO, INC. | Health Technology |
| DEVONIAN HEALTH GROUP INC. | Health Technology |
| Private companies | 5 |
|---|---|
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | Health Technology |
| Philadelphia Education Fund | |
Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Vallon Pharmaceuticals, Inc.
 Vallon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA. | Health Technology |
Benchworks, Inc.
Benchworks, Inc. Miscellaneous Commercial ServicesCommercial Services Benchworks, Inc. engages in the provision of marketing services. It offers brand development and strategy, creative services, print media and non personal promotion, and event planning and management. The company was founded by Thad L. Bench in 1991 and is headquartered in Chestertown, MD. | Commercial Services |
- Stock Market
- Insiders
- David Baker
